Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
1(7%)
Results Posted
75%(9 trials)

Phase Distribution

Ph phase_3
5
33%
Ph not_applicable
1
7%
Ph phase_2
5
33%
Ph phase_4
2
13%

Phase Distribution

0

Early Stage

5

Mid Stage

7

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
2(15.4%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(12)
Other(2)

Detailed Status

Completed12
unknown2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (38.5%)
Phase 35 (38.5%)
Phase 42 (15.4%)
N/A1 (7.7%)

Trials by Status

unknown213%
active_not_recruiting17%
completed1280%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07069569Phase 2

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

Active Not Recruiting
NCT04225715Phase 2

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed
NCT04676724Phase 2

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

Completed
NCT05357235

The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia

Unknown
NCT05357183

The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia

Unknown
NCT01826981Phase 2

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed
NCT01405937Phase 3

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Completed
NCT01370642Phase 3

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Completed
NCT01405560Phase 3

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Completed
NCT01938781Phase 4

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Completed
NCT01962441Phase 3

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Completed
NCT02113631Not Applicable

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Completed
NCT01277601Phase 4

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Completed
NCT01625338Phase 3

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Completed
NCT01204762Phase 2

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15